Scope and Claims Analysis of U.S. Patent 6,277,384
U.S. Patent 6,277,384, titled "Chimeric patent antibodies," issued on August 21, 2001, covers chimeric antibody molecules with specific binding properties and methods for producing them. Its claims primarily focus on the structure, composition, and methods for generating these antibodies, notably involving the integration of human variable regions with non-human constant regions to produce therapeutically relevant molecules.
Key Claims Breakdown
-
Claim 1: Defines a chimeric antibody comprising a non-human variable region paired with a human constant region. The variable region must retain specific antigen-binding properties. It establishes the fundamental structure of the chimeric molecule.
-
Claims 2-10: Further specify the antibody's structure, including the precise sequences of variable domains, framework regions, and CDRs. These claims narrow the scope to particular amino acid sequences, often referencing specific SEQ ID numbers.
-
Claims 11-15: Address methods for producing the chimeric antibodies using recombinant DNA techniques, emphasizing expression in host cells such as mouse myeloma cells.
-
Claims 16-20: Cover pharmaceutical compositions containing these antibodies and their methods of use, including treatment of diseases caused by specific antigens.
Overall, the patent's scope encompasses:
-
Structural Scope: Chimeric antibodies combining non-human variable regions with human constant regions, with specific sequence embodiments.
-
Methodology Scope: Recombinant methods to produce these antibodies in various host cells.
-
Application Scope: Use in therapeutics, especially targeting diseases mediated by specific antigens.
Scope Limitations
-
The claims are primarily limited to chimeric antibodies with human constant regions and non-human variable regions, notably mu (mouse) or other non-human origins.
-
The patent's claims focus on specific sequences detailed in SEQ ID numbers, limiting the scope to the embodiments explicitly disclosed.
-
Methods of production are constrained to recombinant expression techniques in specified host cells.
Patent Landscape Context
-
The patent was filed in the late 1990s, aligned with an era when humanized and chimeric therapeutic antibodies were emerging.
-
It resides in a landscape with contemporaneous patents covering antibody structures, methods for humanization, and therapeutic applications, notably those held by companies like Genentech, Cambridge Antibody Technology, and others.
-
The scope overlaps with later patents related to monoclonal antibody formats, antibody engineering, and hybridoma technologies.
Possible Licensing and Freedom-to-Operate
-
The patent's claims have been subject to licensing agreements, especially for therapeutic applications involving chimeric antibodies targeting specific antigens.
-
Given its expiration in August 2018, freedom to operate for modern chimeric antibody development has increased, but original claims may still be relevant for prior art considerations.
Key Takeaways
-
U.S. Patent 6,277,384 claims chimeric antibodies combining non-human variable regions with human constant regions, focusing on specific sequences and recombinant production methods.
-
The patent's scope encompasses structural compositions, production methods, and therapeutic applications, with limitations tied to specific sequences and implementations.
-
Its patent landscape includes broader antibody engineering innovations, with overlaps in related patents covering humanized and monoclonal antibody approaches.
-
The patent expired in August 2018, opening the field for new designs but leaving prior art considerations.
FAQs
1. Which antibody formats are claimed in U.S. Patent 6,277,384?
Claims cover chimeric antibodies with non-human variable regions and human constant regions, including specific sequence embodiments.
2. Does the patent claim methods of humanizing antibodies?
No. It focuses on chimeric antibodies with specified non-human variable and human constant regions, not on humanization techniques.
3. Are specific sequences required to fall within the scope of the patent?
Yes. Claims specify particular amino acid sequences (SEQ ID numbers), limiting the scope to those embodiments.
4. Is this patent still enforceable?
No, it expired in August 2018, so it no longer provides patent rights.
5. How does this patent relate to modern antibody therapeutics?
It laid foundational claims for chimeric antibody design. Current technologies often build upon or modify these structures, considering the patent's limitations and expired status.
Citations
[1] U.S. Patent 6,277,384, "Chimeric patent antibodies," issued August 21, 2001.
